IT201600084470A1 - Composizione per uso nel trattamento del disturbo depressivo maggiore - Google Patents

Composizione per uso nel trattamento del disturbo depressivo maggiore

Info

Publication number
IT201600084470A1
IT201600084470A1 IT102016000084470A IT201600084470A IT201600084470A1 IT 201600084470 A1 IT201600084470 A1 IT 201600084470A1 IT 102016000084470 A IT102016000084470 A IT 102016000084470A IT 201600084470 A IT201600084470 A IT 201600084470A IT 201600084470 A1 IT201600084470 A1 IT 201600084470A1
Authority
IT
Italy
Prior art keywords
treatment
composition
depressive disorder
major depressive
major
Prior art date
Application number
IT102016000084470A
Other languages
English (en)
Inventor
Giovanni Mogna
Original Assignee
Probiotical Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiotical Spa filed Critical Probiotical Spa
Priority to IT102016000084470A priority Critical patent/IT201600084470A1/it
Priority to CN201780048366.8A priority patent/CN109789171A/zh
Priority to JP2019507089A priority patent/JP7179716B2/ja
Priority to RU2019105678A priority patent/RU2019105678A/ru
Priority to BR112019001039-4A priority patent/BR112019001039A2/pt
Priority to CA3033032A priority patent/CA3033032A1/en
Priority to EP17764450.7A priority patent/EP3496733A1/en
Priority to US16/321,405 priority patent/US11298384B2/en
Priority to PCT/IB2017/054883 priority patent/WO2018029629A1/en
Priority to KR1020197006930A priority patent/KR20190039987A/ko
Publication of IT201600084470A1 publication Critical patent/IT201600084470A1/it
Priority to US17/684,323 priority patent/US11969449B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IT102016000084470A 2016-08-10 2016-08-10 Composizione per uso nel trattamento del disturbo depressivo maggiore IT201600084470A1 (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IT102016000084470A IT201600084470A1 (it) 2016-08-10 2016-08-10 Composizione per uso nel trattamento del disturbo depressivo maggiore
CA3033032A CA3033032A1 (en) 2016-08-10 2017-08-10 Composition for use in the treatment of major depressive disorder
JP2019507089A JP7179716B2 (ja) 2016-08-10 2017-08-10 大鬱病性障害の治療において使用するための組成物
RU2019105678A RU2019105678A (ru) 2016-08-10 2017-08-10 Композиция для применения в лечении большого депрессивного расстройства
BR112019001039-4A BR112019001039A2 (pt) 2016-08-10 2017-08-10 composição para uso no tratamento de transtorno depressivo maior
CN201780048366.8A CN109789171A (zh) 2016-08-10 2017-08-10 用于治疗重度抑郁症的组合物
EP17764450.7A EP3496733A1 (en) 2016-08-10 2017-08-10 Composition for use in the treatment of major depressive disorder
US16/321,405 US11298384B2 (en) 2016-08-10 2017-08-10 Composition for use in the treatment of major depressive disorder
PCT/IB2017/054883 WO2018029629A1 (en) 2016-08-10 2017-08-10 Composition for use in the treatment of major depressive disorder
KR1020197006930A KR20190039987A (ko) 2016-08-10 2017-08-10 주요 우울 장애의 치료용 조성물
US17/684,323 US11969449B2 (en) 2016-08-10 2022-03-01 Composition for use in the treatment of major depressive disorder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102016000084470A IT201600084470A1 (it) 2016-08-10 2016-08-10 Composizione per uso nel trattamento del disturbo depressivo maggiore

Publications (1)

Publication Number Publication Date
IT201600084470A1 true IT201600084470A1 (it) 2018-02-10

Family

ID=57906910

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102016000084470A IT201600084470A1 (it) 2016-08-10 2016-08-10 Composizione per uso nel trattamento del disturbo depressivo maggiore

Country Status (10)

Country Link
US (2) US11298384B2 (it)
EP (1) EP3496733A1 (it)
JP (1) JP7179716B2 (it)
KR (1) KR20190039987A (it)
CN (1) CN109789171A (it)
BR (1) BR112019001039A2 (it)
CA (1) CA3033032A1 (it)
IT (1) IT201600084470A1 (it)
RU (1) RU2019105678A (it)
WO (1) WO2018029629A1 (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679135B2 (en) 2017-12-19 2023-06-20 Probiotical S.P.A. Composition for use in the treatment and/or improvement of sleep and mood disorders
JP7346421B2 (ja) 2017-12-19 2023-09-19 プロバイオティカル・エッセ・ピ・ア 睡眠及び気分障害の治療及び／又は改善における使用のための組成物
KR102340392B1 (ko) * 2018-10-08 2021-12-17 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
TWI731279B (zh) 2018-11-21 2021-06-21 葡萄王生技股份有限公司 發酵乳桿菌gkf3、含其之組合物及改善精神失調之用途
GB201908706D0 (en) * 2019-06-18 2019-07-31 Probi Ab Lactobacillus compositions and uses thereof
EP4265297A1 (en) * 2020-12-16 2023-10-25 Meiji Co., Ltd Composition for improving inflammation of brain tissue
CN113698503B (zh) * 2021-08-16 2022-05-24 华南理工大学 一种植物乳杆菌中性胞外多糖及其应用
CN114947135B (zh) * 2022-05-17 2023-10-24 江苏艾兰得营养品有限公司 一种调节情绪的益生菌组合物、制剂及制备方法和应用
CN116370606A (zh) * 2023-03-09 2023-07-04 南京医科大学 血吸虫来源肽在制备治疗抑郁症药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016065419A1 (en) * 2014-10-28 2016-05-06 Medlab Ip Pty Ltd Treatment for depression and depressive disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
IT1400821B1 (it) 2009-03-09 2013-07-02 Probiotical Spa Sospensione oleosa contenente batteri probiotici per uso pediatrico
CA2779418C (en) 2009-11-11 2018-03-20 Alimentary Health Limited Probiotic bifidobacterium strain
ITMI20110679A1 (it) 2011-04-20 2012-10-21 Giovanni Mogna Composizione comprendente batteri probiotici in grado di ripristinare l effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell iperacidita gastrica.
ITRM20110477A1 (it) * 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITMI20130794A1 (it) * 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle vaginosi batteriche.
WO2016030504A1 (en) * 2014-08-29 2016-03-03 Chr. Hansen A/S Probiotic bifidobacterium adolescentis strains
CN104435100B (zh) 2014-12-29 2016-01-06 青岛大学 一种抗抑郁组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016065419A1 (en) * 2014-10-28 2016-05-06 Medlab Ip Pty Ltd Treatment for depression and depressive disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOGAN A C ET AL: "Major depressive disorder: probiotics may be an adjuvant therapy", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 64, no. 3, 1 January 2005 (2005-01-01), pages 533 - 538, XP004691105, ISSN: 0306-9877, DOI: 10.1016/J.MEHY.2004.08.019 *

Also Published As

Publication number Publication date
US20220193158A1 (en) 2022-06-23
CA3033032A1 (en) 2018-02-15
BR112019001039A2 (pt) 2019-04-30
US11969449B2 (en) 2024-04-30
WO2018029629A1 (en) 2018-02-15
US20210275611A1 (en) 2021-09-09
EP3496733A1 (en) 2019-06-19
JP2019527713A (ja) 2019-10-03
US11298384B2 (en) 2022-04-12
CN109789171A (zh) 2019-05-21
RU2019105678A (ru) 2020-09-17
JP7179716B2 (ja) 2022-11-29
KR20190039987A (ko) 2019-04-16
RU2019105678A3 (it) 2020-12-09

Similar Documents

Publication Publication Date Title
IT201600084470A1 (it) Composizione per uso nel trattamento del disturbo depressivo maggiore
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
IT201600101413A1 (it) Composizione liquida per uso nel trattamento del reflusso gastroesofageo
IL276733A (en) Use of Aribolin in cancer treatment
HK1252813A1 (zh) 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3191103T3 (da) Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
HK1256164A1 (zh) 用於治療神經膠質瘤的製劑
DK3302478T3 (da) Pac-1 kombinations behandling
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
IT201600121617A1 (it) Composizione per il trattamento del reflusso gastroesofageo
DK3373922T3 (da) Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri
GB2581876B (en) Compositions for use in the treatment of endometrial disorder
IT201700111939A1 (it) Composizione farmaceutica per l’uso nel trattamento di stati infiammatori
IT201600093758A1 (it) Insaponificabili di lipidi naturali per l’uso nel trattamento di patologie tumorali
FR3015897B1 (fr) Composition cosmetique capillaire
TH182881B (th) องค์ประกอบสำหรับการใช้ในการบำบัดภาวะภูมิแพ้